Consolidated Statements of Cash Flows (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 745.4	$ 865.0	$ 588.0
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	308.6	294.8	255.5
Share based compensation	87.1	75.7	62.2
Impairment of intangible assets	197.9	16.0	42.7
Gain on sale of non-current investments	(0.5)	(23.5)	(11.1)
(Gain)/loss on sale of product rights	(18.1)	6.0	(16.5)
Other	18.0	16.1	9.1
Movement in deferred taxes	(58.3)	(14.5)	(15.0)
Equity in earnings of equity method investees	(1.0)	(2.5)	(1.4)
Changes in operating assets and liabilities:
Decrease/(increase) in accounts receivable	22.2	(134.0)	(114.4)
Increase in sales deduction accrual	42.7	80.5	222.6
Increase in inventory	(88.2)	(64.4)	(58.2)
Increase in prepayments and other assets	(14.5)	(36.8)	(40.3)
Increase/(decrease) in accounts and notes payable and other liabilities	136.7	(10.0)	25.9
Returns on investment from joint venture	4.9	5.2	5.8
Net cash provided by operating activities	1,382.9	1,073.6	954.9
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash	3.5	6.2	6.3
Purchases of subsidiary undertakings and businesses, net of cash acquired	(97.0)	(725.0)	(449.6)
Payments on foreign exchange contracts related to Movetis NV ("Movetis") acquisition	0	0	(33.4)
Purchases of non-current investments	(18.0)	(10.7)	(2.9)
Purchases of property, plant and equipment ("PPE")	(149.6)	(194.3)	(326.6)
Purchases of intangible assets	(43.5)	(5.2)	(2.7)
Proceeds from disposal of non-current investments and PP&E	7.2	106.0	2.3
Proceeds from capital expenditure grants	8.4	0	0
Proceeds received on sales of product rights	17.8	12.0	2.0
Returns of equity investments and proceeds from short term investments	0.2	1.8	7.2
Net cash used in investing activities	(271.0)	(809.2)	(797.4)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from drawing of revolving credit facility ("RCF")	0	30.0	0
Repayment of RCF	0	(30.0)	0
Repayment of debt acquired through business combinations	(3.0)	(13.1)	0
Extinguishment of building finance obligation	0	0	(43.1)
Excess tax benefit associated with exercise of stock options	40.7	31.4	6.5
Payments to acquire shares	(205.8)	(151.8)	(1.7)
Proceeds from exercise of options	16.2	13.4	11.2
Payment of facility arrangement costs	0	0	(8.0)
Deferred contingent consideration payments	(5.8)	0	0
Payment of dividend	(86.3)	(73.8)	(62.0)
Other	(0.3)	(1.5)	(2.4)
Net cash used in financing activities	(244.3)	(195.4)	(99.5)
Effect of foreign exchange rate changes on cash and cash equivalents	(5.4)	0.4	(6.3)
Net increase in cash and cash equivalents	862.2	69.4	51.7
Cash and cash equivalents at beginning of period	620.0	550.6	498.9
Cash and cash equivalents at end of period	1,482.2	620.0	550.6
Supplemental information associated with continuing operations:
Interest paid	(34.6)	(33.3)	(25.9)
Income taxes paid	(199.2)	(286.1)	(329.2)
Non cash investing and financing activities:
Equity in Vertex Pharmaceuticals, Inc. ("Vertex") received as part consideration for disposal of non-current investment in Virochem Pharma, Inc. ("Virochem")	0	0	9.1
EBT
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments to acquire shares	(99.3)	(151.8)	(1.7)
Share Buy-back Program
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments to acquire shares	$ (106.5)	$ 0	$ 0